Results 171 to 180 of about 1,466,333 (379)

Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody [PDF]

open access: bronze, 1997
Frank Hartmann   +7 more
openalex   +1 more source

Hemophilia A: An Ideal Disease for Prenatal Therapy

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada   +2 more
wiley   +1 more source

Human immunodeficiency virus neutralizing antibodies and methods of use thereof [APPLICATION] [PDF]

open access: yes, 2014
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of ...
Bjorkman, Pamela J.   +3 more
core  

Targeting T cells against brain tumors with a bispecific ligand‐antibody conjugate [PDF]

open access: bronze, 1998
Edward J. Roy   +4 more
openalex   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

[Bispecific antibodies: what future?].

open access: yesMedecine sciences : M/S, 2009
Monoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR-expressing cells. Attempts to improve the cytotoxicity of antibodies, particularly in the cancer field, have led to the design
Pèlegrin, André, Robert, Bruno
openaire   +2 more sources

Construction of a diabody (small recombinant bispecific antibody) using a refolding system [PDF]

open access: bronze, 2000
Shin-ichi Takemura   +12 more
openalex   +1 more source

Potential roles of antibodies with different classes in IgG4‐related diseases

open access: yesRheumatology &Autoimmunity, EarlyView.
This review discussed the common characteristics of different classes of antibodies and their potential corresponding unique mechanisms involved in immunoglobulin G4‐related disease. Abstract Immunoglobulin G4‐related disease (IgG4‐RD), first identified two decades ago, is an immune‐mediated pro‐inflammatory and profibrotic disease entity affecting ...
Ling Li   +6 more
wiley   +1 more source

A REVIEW ON BISPECIFIC ANTIBODIES

open access: yes, 2019
Antibodies are widely recognized for their therapeutic potential and subsequently have prompted a lot of interest into their development and application. The structure of monoclonal IgG antibody is represented, with the heavy chains in rose and the light chains in green.
openaire   +1 more source

CD3 directed bispecific antibodies induce increased lymphocyte–endothelial cell interactions in vitro [PDF]

open access: hybrid, 2000
Grietje Molema   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy